HUE037890T2 - Sclerosis tuberosa kezelése - Google Patents

Sclerosis tuberosa kezelése

Info

Publication number
HUE037890T2
HUE037890T2 HUE07711417A HUE07711417A HUE037890T2 HU E037890 T2 HUE037890 T2 HU E037890T2 HU E07711417 A HUE07711417 A HU E07711417A HU E07711417 A HUE07711417 A HU E07711417A HU E037890 T2 HUE037890 T2 HU E037890T2
Authority
HU
Hungary
Prior art keywords
tuberous sclerosis
sclerosis treatment
treatment
tuberous
sclerosis
Prior art date
Application number
HUE07711417A
Other languages
English (en)
Inventor
William Berg
John Benedetto
Ingrid Elmroth
Heidi Lane
David Lebwohl
William Sellers
Michael Stumm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37944274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE037890(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602123A external-priority patent/GB0602123D0/en
Priority claimed from GB0603568A external-priority patent/GB0603568D0/en
Priority claimed from GB0604593A external-priority patent/GB0604593D0/en
Priority claimed from GB0605760A external-priority patent/GB0605760D0/en
Priority claimed from GB0609698A external-priority patent/GB0609698D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE037890T2 publication Critical patent/HUE037890T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE07711417A 2006-02-02 2007-01-31 Sclerosis tuberosa kezelése HUE037890T2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0602123A GB0602123D0 (en) 2006-02-02 2006-02-02 Organic compounds
GB0603568A GB0603568D0 (en) 2006-02-22 2006-02-22 Organic compounds
GB0604593A GB0604593D0 (en) 2006-03-07 2006-03-07 Organic compounds
GB0605760A GB0605760D0 (en) 2006-03-22 2006-03-22 Organic compounds
GB0609698A GB0609698D0 (en) 2006-05-16 2006-05-16 Organic compounds

Publications (1)

Publication Number Publication Date
HUE037890T2 true HUE037890T2 (hu) 2018-09-28

Family

ID=37944274

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07711417A HUE037890T2 (hu) 2006-02-02 2007-01-31 Sclerosis tuberosa kezelése

Country Status (21)

Country Link
US (1) US20100305150A1 (hu)
EP (2) EP1983984B1 (hu)
JP (2) JP5639743B2 (hu)
KR (2) KR20140016439A (hu)
CN (1) CN104000818B (hu)
AU (1) AU2007211613C1 (hu)
BR (1) BRPI0707684B1 (hu)
CA (1) CA2637255C (hu)
CY (1) CY1120741T1 (hu)
DK (1) DK1983984T3 (hu)
ES (1) ES2672627T3 (hu)
HK (1) HK1251156A1 (hu)
HU (1) HUE037890T2 (hu)
LT (1) LT1983984T (hu)
MX (1) MX339116B (hu)
PL (1) PL1983984T3 (hu)
PT (1) PT1983984T (hu)
RU (1) RU2473343C2 (hu)
SI (1) SI1983984T1 (hu)
TR (1) TR201807065T4 (hu)
WO (1) WO2007088034A2 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037890T2 (hu) 2006-02-02 2018-09-28 Novartis Ag Sclerosis tuberosa kezelése
WO2012047587A2 (en) * 2010-09-27 2012-04-12 Serrata, Llc Mdm2 inhibitors for treatment of ocular conditions
JP5652795B2 (ja) * 2011-01-31 2015-01-14 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
WO2013074583A1 (en) * 2011-11-14 2013-05-23 The Broad Institute, Inc. Treatment and prognosis of lymphangioleiomyomatosis
JP6328146B2 (ja) 2013-02-01 2018-05-23 グリアロジクス・インコーポレイテッドＧｌｉａｌｏｇｉｘ， Ｉｎｃ． 神経変性およびその他の疾患の治療用組成物および方法
US9925202B2 (en) 2013-03-04 2018-03-27 Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
EP2976074B1 (en) 2013-03-19 2020-01-01 Universitat Pompeu-Fabra Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
MX2016010373A (es) 2014-02-11 2016-11-30 Lam Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUE062742T2 (hu) 2014-04-04 2023-12-28 Ai Therapeutics Inc Belélegezhetõ rapamicin készítmény életkorral kapcsolatos állapotok kezelésére
MX2017004440A (es) 2014-10-07 2017-11-01 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
BR112019002689A2 (pt) 2016-08-10 2019-05-14 Univ Texas terapia com rapamicina tópica
KR20210130769A (ko) 2019-02-20 2021-11-01 에이아이 테라퓨틱스, 인코포레이티드 국소 라파마이신 제형 및 안면 혈관섬유종 및 다른 피부 장애에서의 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
HU228234B1 (en) * 1995-06-09 2013-02-28 Novartis Ag Rapamycin derivatives, pharmaceutical compositions containing them and their use
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
SI2762140T1 (sl) 2001-02-19 2017-07-31 Novartis Ag Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20040266811A1 (en) * 2002-11-08 2004-12-30 Weinstein David E. Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
EP1599212A4 (en) 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
EP1646634B1 (en) * 2003-07-08 2008-11-12 Novartis AG Use of rapamycin and rapamycin derivatives for the treatment of bone loss
WO2005016252A2 (en) * 2003-07-11 2005-02-24 Ariad Gene Therapeutics, Inc. Phosphorus-containing macrocycles
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
HUE037890T2 (hu) 2006-02-02 2018-09-28 Novartis Ag Sclerosis tuberosa kezelése

Also Published As

Publication number Publication date
AU2007211613B2 (en) 2011-04-28
BRPI0707684A2 (pt) 2011-05-10
EP1983984A2 (en) 2008-10-29
SI1983984T1 (en) 2018-06-29
LT1983984T (lt) 2018-06-11
WO2007088034A2 (en) 2007-08-09
WO2007088034A3 (en) 2007-11-01
RU2473343C2 (ru) 2013-01-27
CY1120741T1 (el) 2019-12-11
HK1251156A1 (zh) 2019-01-25
PL1983984T3 (pl) 2018-08-31
DK1983984T3 (en) 2018-06-14
EP1983984B1 (en) 2018-03-07
JP2013224298A (ja) 2013-10-31
ES2672627T3 (es) 2018-06-15
CA2637255C (en) 2018-06-12
PT1983984T (pt) 2018-06-14
KR20140016439A (ko) 2014-02-07
AU2007211613A1 (en) 2007-08-09
BRPI0707684A8 (pt) 2017-12-26
RU2008135131A (ru) 2010-03-10
CN104000818B (zh) 2017-11-21
KR20080090493A (ko) 2008-10-08
EP3348265A1 (en) 2018-07-18
MX339116B (es) 2016-05-12
AU2007211613C1 (en) 2018-01-04
US20100305150A1 (en) 2010-12-02
CN104000818A (zh) 2014-08-27
JP5639743B2 (ja) 2014-12-10
CA2637255A1 (en) 2007-08-09
JP2009525294A (ja) 2009-07-09
TR201807065T4 (tr) 2018-06-21
BRPI0707684B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
HK1251156A1 (zh) 結節性硬化症治療
GB0624874D0 (en) Treatment
IL181378A0 (en) Liquid-mixing infusor
GB0606604D0 (en) Treatment apparatus
PL2061385T3 (pl) Urządzenie do zabiegów naczyniowych
GB0600692D0 (en) Well treatment
IL197818A0 (en) Multiple sclerosis therapy
GB0718523D0 (en) Agricultural treatment
GB0616226D0 (en) Processes
GB0600914D0 (en) Process
GB0621527D0 (en) Acne treatment
GB0604874D0 (en) Process
GB0607952D0 (en) Novel treatment
GB0604233D0 (en) Process
GB0511769D0 (en) Treatment
GB0604460D0 (en) Treatment
GB2444117B (en) Food treatment
GB0716608D0 (en) Distortion-tolerant processing
GB0608402D0 (en) Thyroid treatment
GB0602857D0 (en) The treatment of sialorrhoea
GB2441499B (en) Slimming Spray
GB0603232D0 (en) Process
GB0614058D0 (en) Treatment for multiple sclerosis
GB0609792D0 (en) The treatment of multiple sclerosis
GB0610431D0 (en) Treatment